Spots Global Cancer Trial Database for uterine corpus leiomyosarcoma

Every month we try and update this database with for uterine corpus leiomyosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma	NCT03880019	Stage III Uteri... Stage IV Uterin... Uterine Corpus ...	Computed Tomogr... Core Biopsy Magnetic Resona... Olaparib Temozolomide	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus	NCT00031629	Recurrent Uteri... Uterine Corpus ...	Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim	18 Years -	GOG Foundation
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus	NCT00031629	Recurrent Uteri... Uterine Corpus ...	Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim	18 Years -	GOG Foundation
Collecting Tumor Samples From Patients With Gynecological Tumors	NCT00897442	Borderline Ovar... Borderline Ovar... Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Childhood Embry... Childhood Malig... Endometrioid St... Gestational Tro... Malignant Mesot... Malignant Ovari... Melanoma Neoplasm of Unc... Ovarian Brenner... Ovarian Clear C... Ovarian Serous ... Paget Disease o... Recurrent Cervi... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Vagin... Recurrent Vulva... Stage I Ovarian... Stage I Uterine... Stage I Vaginal... Stage I Vulvar ... Stage IA Cervic... Stage IA Fallop... Stage IA Ovaria... Stage IA Ovaria... Stage IB Cervic... Stage IB Fallop... Stage IB Ovaria... Stage IB Ovaria... Stage IC Fallop... Stage IC Ovaria... Stage IC Ovaria... Stage II Ovaria... Stage II Uterin... Stage II Vagina... Stage II Vulvar... Stage IIA Cervi... Stage IIA Fallo... Stage IIA Ovari... Stage IIA Ovari... Stage IIB Cervi... Stage IIB Fallo... Stage IIB Ovari... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIC Ovari... Stage III Borde... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage III Vulva... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Border... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IVA Cervi... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Vagin... Stage IVB Vulva... Uterine Corpus ... Uterine Corpus ... Vulvar Squamous...	Laboratory Biom...	-	GOG Foundation
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma	NCT02428192	Metastatic Leio... Unresectable Le... Uterine Corpus ...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	NCT01637961	Recurrent Uteri... Uterine Corpus ...	Alisertib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery	NCT01958580	Stage IA Uterin... Stage IB Uterin... Stage IC Uterin... Stage IIA Uteri... Stage IIB Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ...	Gemcitabine Hyd... Docetaxel Internal Radiat... Intensity-Modul... External Beam R... Laboratory Biom...	18 Years -	Albert Einstein College of Medicine
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma	NCT01012297	Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ...	Bevacizumab Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim Placebo	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery	NCT01533207	Stage I Uterine... Uterine Corpus ...	Clinical Observ... Docetaxel Doxorubicin Hyd... Filgrastim Gemcitabine Hyd... Pegfilgrastim	18 Years -	GOG Foundation
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	NCT01637961	Recurrent Uteri... Uterine Corpus ...	Alisertib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma	NCT02428192	Metastatic Leio... Unresectable Le... Uterine Corpus ...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus	NCT00025220	Recurrent Uteri... Uterine Corpus ...	Thalidomide Laboratory Biom...	-	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery	NCT01958580	Stage IA Uterin... Stage IB Uterin... Stage IC Uterin... Stage IIA Uteri... Stage IIB Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ...	Gemcitabine Hyd... Docetaxel Internal Radiat... Intensity-Modul... External Beam R... Laboratory Biom...	18 Years -	Albert Einstein College of Medicine
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy	NCT01220609	Recurrent Uteri... Uterine Corpus ...	Ixabepilone Laboratory Biom...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: